Question · asked by 1 review

Inhaled corticosteroids plus standard care vs placebo or usual care: Resolution of symptoms

Inhaled corticosteroids plus standard care probably leads to higher symptom resolution: all initial symptoms resolved at day 14 compared with standard care (with or without placebo) (moderate certainty).

What each review found

Include earlier review versions
FindingEffectStudiesGRADE certainty
Inhaled corticosteroids plus standard care vs standard care (with or without placebo)
Symptom resolution: all initial symptoms resolved at day 14 · adults with a confirmed diagnosis of mild COVID‐19, of whom only 10% (219/2132) participants had received ≥ 1…
Inhaled corticosteroids plus standard care probably leads to higher symptom resolution: all initial symptoms resolved at day 14 compared with standard care (with or without placebo) (moderate certainty).
Inhaled corticosteroids for the treatment of COVID‐19 (2022) · Cochrane Headline outcomes only
RR 1.19 [1.09, 1.3]2 studies · 1986 participantsModerate

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Inhaled corticosteroids for the treatment of COVID‐19
2022 · Cochrane Headline outcomes only
Not reportedlist not extracted yetNot assessed

Studies behind the findings

None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.

How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.